Last reviewed · How we verify

NCT01315639: BALTAZAR

New Biomarker for Alzheimer's Disease Diagnostic

Completed NA Last updated 12 September 2025
What this trial tests

NA trial testing biomarkers, MRI and CSF in Alzheimer's Disease in 1,067 participants. Completed in 16 March 2018.

Timeline
3 September 2010
Primary endpoint
26 February 2015
16 March 2018

Quick facts

Lead sponsorAssistance Publique - Hôpitaux de Paris
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment1,067
Start date3 September 2010
Primary completion26 February 2015
Estimated completion16 March 2018
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

45 and older, any sex, with Alzheimer's Disease or Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to examine the relationship between plasma putative biomarkers for Alzheimer's disease (i.e. Ab40 amyloid and total Ab42 amyloid, free, bound, free/bound, truncated, sAPPα) and : * the risk of conversion of individuals with Mild Cognitive Impairment (MCI) into Alzheimer's disease (AD), * the Alzheimer's disease progression rate.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function.
    Lehmann S, Schraen-Maschke S, Vidal JS, Delaby C, et al · · 2023 · cited 56× · PMID 37012068 · DOI 10.1136/jnnp-2022-330540
  2. Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment.
    Lehmann S, Schraen-Maschke S, Vidal JS, Delaby C, et al · · 2024 · cited 43× · PMID 38658136 · DOI 10.1136/jnnp-2024-333467
  3. Clarifying the association of CSF Aβ, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer disease.
    Lehmann S, Schraen-Maschke S, Buée L, Vidal JS, et al · · 2024 · cited 16× · PMID 39380095 · DOI 10.1186/s13024-024-00755-3
  4. Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer's Disease Continuum.
    Lehmann S, Schraen-Maschke S, Vidal JS, Blanc F, et al · · 2023 · cited 14× · PMID 38139190 · DOI 10.3390/ijms242417361
  5. Head-to-Head Comparison of Two Plasma Phospho-tau Assays in Predicting Conversion of Mild Cognitive Impairment to Dementia.
    Lehmann S, Schraen-Maschke S, Vidal JS, Delaby C, et al · · 2023 · cited 9× · PMID 37654065 · DOI 10.1093/clinchem/hvad103
  6. Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ<sub>1-42</sub> and Tau Proteins in Elderly Patients With Mild Cognitive Impairment.
    Duron E, Vidal JS, Grousselle D, Gabelle A, et al · · 2018 · cited 7× · PMID 30327597 · DOI 10.3389/fnagi.2018.00297
  7. Association of caffeine consumption with cerebrospinal fluid biomarkers in mild cognitive impairment and Alzheimer's disease: A BALTAZAR cohort study.
    Blum D, Cailliau E, Béhal H, Vidal JS, et al · · 2024 · cited 5× · PMID 39099181 · DOI 10.1002/alz.14169
  8. Beyond amyloid and tau: synaptic and neurodegenerative biomarkers shape MCI progression
    Delaby C, Schraen-Maschke S, Paquet C, Blanc F, et al · · 2025 · DOI 10.1101/2025.10.06.25337445

Verify or expand the search:

Other recruiting trials for Alzheimer's Disease

Currently open trials in the same condition.

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01315639.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing